AIRLINK 151.71 Decreased By ▼ -4.00 (-2.57%)
BOP 10.05 Decreased By ▼ -0.26 (-2.52%)
CNERGY 7.30 Decreased By ▼ -0.35 (-4.58%)
CPHL 85.11 Decreased By ▼ -3.06 (-3.47%)
FCCL 46.57 Decreased By ▼ -0.79 (-1.67%)
FFL 15.78 Decreased By ▼ -0.34 (-2.11%)
FLYNG 54.86 Decreased By ▼ -3.15 (-5.43%)
HUBC 136.89 Decreased By ▼ -1.63 (-1.18%)
HUMNL 11.25 Decreased By ▼ -0.29 (-2.51%)
KEL 5.34 Decreased By ▼ -0.13 (-2.38%)
KOSM 5.63 Increased By ▲ 0.17 (3.11%)
MLCF 82.84 Decreased By ▼ -0.91 (-1.09%)
OGDC 208.86 Decreased By ▼ -3.19 (-1.5%)
PACE 6.05 Increased By ▲ 0.19 (3.24%)
PAEL 41.46 Decreased By ▼ -1.76 (-4.07%)
PIAHCLA 22.38 Increased By ▲ 0.62 (2.85%)
PIBTL 8.19 Decreased By ▼ -0.23 (-2.73%)
POWER 13.80 Decreased By ▼ -0.56 (-3.9%)
PPL 167.09 Decreased By ▼ -3.90 (-2.28%)
PRL 32.17 Decreased By ▼ -1.32 (-3.94%)
PTC 24.43 Decreased By ▼ -1.07 (-4.2%)
SEARL 89.83 Decreased By ▼ -3.06 (-3.29%)
SSGC 41.52 Decreased By ▼ -0.40 (-0.95%)
SYM 14.86 Decreased By ▼ -0.14 (-0.93%)
TELE 7.69 Decreased By ▼ -0.13 (-1.66%)
TPLP 9.14 Decreased By ▼ -0.17 (-1.83%)
TRG 63.20 Decreased By ▼ -1.02 (-1.59%)
WAVESAPP 9.14 Decreased By ▼ -0.28 (-2.97%)
WTL 1.45 Increased By ▲ 0.08 (5.84%)
YOUW 4.15 Decreased By ▼ -0.04 (-0.95%)
BR100 13,037 Decreased By -207.6 (-1.57%)
BR30 37,726 Decreased By -745.3 (-1.94%)
KSE100 122,144 Decreased By -1949.6 (-1.57%)
KSE30 36,883 Decreased By -653.4 (-1.74%)

Pfizer Inc and Germany's BioNTech SE are expected to submit an emergency use authorization request as early as Tuesday to the US Food and Drug Administration (FDA) for vaccines for children aged six months to 5 years, the Washington Post reported on Monday.

Coronavirus vaccines for children younger than 5 could be available as soon as end-February under a plan that would lead to the potential authorization of a two-shot regimen in the coming weeks, the Post reported, citing people briefed on the situation.

The report says that the FDA urged the companies to submit the application so that regulators could begin reviewing the two-shot data.

EU watchdog approves Pfizer Covid pill

"The idea is, let's go ahead and start the review of two doses," the report quoted one of the people familiar with the situation as saying. "If the data holds up in the submission, you could start kids on their primary baseline months earlier than if you don't do anything until the third-dose data comes in."

Pfizer, BioNTech and the FDA did not immediately respond to Reuters requests for comment.

Pfizer said in January it expected the latest results from a clinical trial for kids under the age of 5 by April, after it amended its study to give a third dose to everybody who's less than five at least eight weeks after their last vaccination.

The company amended the study because children between the ages of 2 and 4 who were given two 3-microgram doses of the vaccine did not have the same immune response that a larger dose of the vaccine generated in older children.

Comments

Comments are closed.